Figure 3.
Outcomes in patients with lenalidomide-refractory RRMM by number of LOT. (A) TTNT, (B) RW-PFS, and (C) OS.

Outcomes in patients with lenalidomide-refractory RRMM by number of LOT. (A) TTNT, (B) RW-PFS, and (C) OS.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal